Negative late-stage trial results for Sanofi's iniparib and otamixaban

3 June 2013

There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as the company revealed negative top-line results from the Phase III ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC).

In the study, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone. The results do not support further development of iniparib in this patient population.

As a result, Sanofi has decided to fully impair the intangible assets of iniparib on the June 30, 2013 consolidated balance sheet. The related charge will have an estimated net impact of $285 million after tax on consolidated net income (around 219 million euros). The non-cash charge will not have an impact on business net income, the company stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK